The objectives of this study were to evaluate a panel of monoclonal antibodies (MUC1, p16, ER, PR, and vimentin), and assess their diagnostic value in distinguishing between primary endocervical adenocarcinoma (ECA), and primary endometrial mucinous adenocarcinoma (EMMA). This evidence concerns the gene MUC1 and endocervical adenocarcinoma.